Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
50 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Thrombotic Thrombocytopenic Purpura - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Thrombotic Thrombocytopenic Purpura - Pipeline Review, H2 2014', provides an overview of the Thrombotic Thrombocytopenic Purpura's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Thrombotic Thrombocytopenic Purpura, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombotic Thrombocytopenic Purpura and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Thrombotic Thrombocytopenic Purpura - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Thrombotic Thrombocytopenic Purpura and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Thrombotic Thrombocytopenic Purpura products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Thrombotic Thrombocytopenic Purpura pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Thrombotic Thrombocytopenic Purpura - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Thrombotic Thrombocytopenic Purpura pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Thrombotic Thrombocytopenic Purpura Overview 6 Therapeutics Development 7 Pipeline Products for Thrombotic Thrombocytopenic Purpura - Overview 7 Pipeline Products for Thrombotic Thrombocytopenic Purpura - Comparative Analysis 8 Thrombotic Thrombocytopenic Purpura - Therapeutics under Development by Companies 9 Thrombotic Thrombocytopenic Purpura - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Thrombotic Thrombocytopenic Purpura - Products under Development by Companies 13 Thrombotic Thrombocytopenic Purpura - Companies Involved in Therapeutics Development 14 Ablynx NV 14 Kaketsuken K.K. 15 Glenmark Pharmaceuticals Ltd. 16 Octapharma AG 17 Archemix Corp. 18 Omeros Corporation 19 Thrombotic Thrombocytopenic Purpura - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 plasma (human) - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 OMS-721 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 caplacizumab - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Recombinant Enzyme to Target ADAMTS-13 for Thrombotic Thrombocytopenic Purpura - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 GBR-600 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 ARC-15105 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Thrombotic Thrombocytopenic Purpura - Recent Pipeline Updates 38 Thrombotic Thrombocytopenic Purpura - Dormant Projects 42 Thrombotic Thrombocytopenic Purpura - Product Development Milestones 43 Featured News & Press Releases 43 Jun 17, 2014: Ablynx's Anti-vWF Nanobody, Caplacizumab, achieves Clinical Proof-of-concept in Phase II Titan Study 43 Apr 03, 2014: Investigational New Drug Application Cleared by FDA for OMS721 in Thrombotic Microangiopathies 44 Apr 16, 2012: Baxter And Halozyme Provide Update On HyQ Biologics License Application 45 Jul 28, 2011: Initial Observations Of ABLYNX'S PHASE II TTP Program Presented At ISTH Congress 45 Sep 30, 2010: Ablynx Initiates Phase II Clinical Trial For ALX-0081 46 Sep 30, 2010: Ablynx Initiates Phase II Clinical Trial For Thrombotic Thrombocytopenic Purpura 47 Sep 30, 2010: Ablynx Initiates Phase II Clinical Trial For Thrombotic Thrombocytopenic Purpura 47 Aug 27, 2010: Octapharma Successfully Completes Uniplas Clinical Development 48 Appendix 49 Methodology 49 Coverage 49 Secondary Research 49 Primary Research 49 Expert Panel Validation 49 Contact Us 50 Disclaimer 50
List of Tables Number of Products under Development for Thrombotic Thrombocytopenic Purpura, H2 2014 7 Number of Products under Development for Thrombotic Thrombocytopenic Purpura - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Comparative Analysis by Late Stage Development, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Comparative Analysis by Early Stage Development, H2 2014 12 Products under Development by Companies, H2 2014 13 Thrombotic Thrombocytopenic Purpura - Pipeline by Ablynx NV, H2 2014 14 Thrombotic Thrombocytopenic Purpura - Pipeline by Kaketsuken K.K., H2 2014 15 Thrombotic Thrombocytopenic Purpura - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2014 16 Thrombotic Thrombocytopenic Purpura - Pipeline by Octapharma AG, H2 2014 17 Thrombotic Thrombocytopenic Purpura - Pipeline by Archemix Corp., H2 2014 18 Thrombotic Thrombocytopenic Purpura - Pipeline by Omeros Corporation, H2 2014 19 Assessment by Monotherapy Products, H2 2014 20 Number of Products by Stage and Target, H2 2014 22 Number of Products by Stage and Mechanism of Action, H2 2014 24 Number of Products by Stage and Route of Administration, H2 2014 26 Number of Products by Stage and Molecule Type, H2 2014 28 Thrombotic Thrombocytopenic Purpura Therapeutics - Recent Pipeline Updates, H2 2014 38 Thrombotic Thrombocytopenic Purpura - Dormant Projects, H2 2014 42
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
